At the time of writing, Legend Biotech Corp ADR [LEGN] stock is trading at $67.00, up 1.36%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LEGN shares have gain 15.30% over the last week, with a monthly amount glided 15.26%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 23, February 2024, Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy. In a post published today on Yahoo Finance, CARVYKTI® is the first CAR-T therapy for patients with relapsed and refractory multiple myeloma to receive a positive CHMP opinion for second line treatment.
From an analyst’s perspective:
Previously, Goldman started tracking the stock with Buy rating on November 06, 2023, and set its price target to $90.09. On May 25, 2023, William Blair initiated with a Mkt Perform rating and assigned a price target of $64 on the stock. Daiwa Securities started tracking the stock assigning a Buy rating. H.C. Wainwright initiated its recommendation with a Buy and recommended $66 as its price target on March 29, 2023. RBC Capital Mkts started tracking with a Outperform rating for this stock on March 24, 2023, and assigned it a price target of $73. In a note dated December 06, 2022, UBS initiated an Buy rating and provided a target price of $66 on this stock.
For the past year, the stock price of Legend Biotech Corp ADR fluctuated between $42.90 and $77.32. Currently, Wall Street analysts expect the stock to reach $66 within the next 12 months. Legend Biotech Corp ADR [NASDAQ: LEGN] shares were valued at $67.00 at the most recent close of the market. An investor can expect a potential drop of -1.49% based on the average LEGN price forecast.
Analyzing the LEGN fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 65.60 points at the first support level, and at 64.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 68.91, and for the 2nd resistance point, it is at 70.81.
Legend Biotech Corp ADR [LEGN] reported earnings per share of -$0.34 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.68/share, meaning a difference of $0.34 and a surprise factor of 50.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$1.14 per share as compared to estimates of -$0.6 per share, a difference of -$0.54 representing a surprise of -90.00%.
Ratios To Look Out For
It is important to note that Legend Biotech Corp ADR [NASDAQ:LEGN] has a current ratio of 8.61. Also, the Quick Ratio is 8.51, while the Cash Ratio stands at 0.05.
